山东步长制药股份有限公司 关于公司产品续约成功保留在国家医保目录的公告

Group 1 - The company successfully renewed the inclusion of its products, Xuanfei Baidu Granules and Danhong Injection, in the National Medical Insurance Catalog for 2025 [1][3] - Xuanfei Baidu Granules are indicated for clearing heat and detoxifying, used for epidemic diseases caused by damp-heat obstructing the lungs, with symptoms including fever, cough, and shortness of breath [1][2] - Danhong Injection is indicated for activating blood circulation and relieving obstruction, used for chest pain and stroke caused by blood stasis, with symptoms including chest pain, palpitations, and limb numbness [2] Group 2 - The National Medical Insurance Catalog will officially take effect on January 1, 2026, with specific execution requirements to be determined by government departments [3] - The sales performance of the drugs may be influenced by multiple factors, including changes in the market environment, leading to uncertainty [3]